November 17 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] said on Thursday its consolidated net profit rose 26% on the year to 301.7 million euro ($313.2 million) in the first nine months of 2022.
Consolidated sales revenue increased by an annual 6% to 1.242 billion euro in January-September, with 94% of the total coming from sales abroad, Krka said in a statement on the group's preliminary operating results for the nine-month period.
The nine-month operating profit (EBIT) of the Krka group fell 14% on the year to 233.8 million euro, while the operating profit before depreciation and amortisation (EBITDA) went down 11% to 314.2 million euro.
The Krka group allocated 74.9 million euro to investments in the first nine months of 2022, of which 53.1 million euro to the controlling company.
The group employed 11,489 workers at the end of September, Krka said.
Eastern Europe generated the highest sales within the group - of 414.1 million euro, up 4% on the year, with product sales in Russia - Krka's largest individual market, rising 5%, to 251.3 million euro.
Sales in Central Europe rose 3% on the year to 280.9 million euro in January-September, followed by sales of 242.4 million euro in Western Europe, up by an annual 6%.
Sales in Southeast Europe grew 5% to 172.8 million euro in the period under review, whereas sales in Slovenia increased 12% to 77.2 million euro and sales in the Overseas Markets segment went up 18% to 49.1 million euro.
($ = 0.9634 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here